Hypercholesterolemia is a strong predictor of cardiovascular diseases. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase gene (Hmgcr) coding for the rate-limiting enzyme in the cholesterol biosynthesis pathway is a crucial regulator of plasma cholesterol levels. However, the post-transcriptional regulation of Hmgcr remains poorly understood. The main objective of this study was to explore the role of miRNAs in the regulation of Hmgcr expression.
INTRODUCTION
Cardiovascular diseases (CVDs) remain the leading cause of global mortality and morbidity [1] . Among various determinants of CVDs, plasma cholesterol is an important factor contributing to multiple disease states including atherosclerosis, coronary artery disease, obesity, hypertension and type 2 diabetes [2] [3] [4] . 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase gene (human: HMGCR, mouse/rat: Hmgcr) that codes for a ~ 97 kDa endoplasmic-reticulum membrane glycoprotein catalyzing the rate-limiting step in the cholesterol biosynthesis pathway [5] is, therefore, a critical modulator of dyslipidemia and consequent CVDs.
Statins, HMG-CoA reductase inhibitors, are widely used to reduce high cholesterol levels and risk of CVDs [6] . HMGCR expression/enzyme activity is modulated by feedback control mechanisms involving sterols and nonsterols at transcriptional and post-translational levels by family of sterol regulatory element binding proteins (SREBPs), SREBP cleavage activated protein (SCAP), and insulin induced genes (Insig1 and Insig2) [7] . However, the molecular mechanisms regulating Hmgcr expression at the post-transcriptional level are poorly understood.
MicroRNAs (miRNAs) are small noncoding RNAs that control gene expression by translational repression and/or mRNA degradation. Recent studies have revealed that miRNAs play important roles in cardiovascular physiology, and pathophysiology [8, 9] . We performed systematic computational and extensive experimental analyses that revealed a crucial role for miR-27a in the post-transcriptional regulation of Hmgcr under basal and elevated cholesterol conditions. This study also highlights the previously unknown role of Egr1 in miR-27a expression.
Interestingly, miR-27a targets multiple genes in addition to Hmgcr in cholesterol biosynthesis. In line with these in vitro findings, miRNA-27a represses Hmgcr expression in liver tissues and modulates plasma cholesterol levels in high cholesterol diet-fed Apoe -/mice.
MATERIALS AND METHODS.

Comparative genomics analyses.
For rat QTL analysis, data pertaining to elevated lipid/cholesterol-QTLs, their respective LOD scores and all the genes with their respective positions in a particular QTL was mined from the Rat Genome Database (Table S1 ). Each QTL is designated a 'Logarithm of odds' (LOD) score which is a measure of strength of evidence for the presence of a QTL at a particular location and its association to a trait. The elevated lipid/cholesterol-QTLs in rats were plotted against 5 For correlation analysis, human tissues that showed consistent HMGCR expression across GTEx, BioGPS and SAGE (Table S2 ) databases were selected for analysis. The expression of HMGCR across various human tissues was mined from the GTEx portal (Table S2) . Likewise, tissue-specific hsa-miR-27a-3p expression was obtained from DASHR (Table S2 ). Further, tissues showing hsa-miR-27a-3p expression in the range of 100-1000 RPM were selected since miRNAs expressed in this range were reported to bring about significant target repression [10] . Only tissues common to the GTEx portal and DASHR were chosen for correlation analysis. The data was normalized to a particular tissue (having the lowest expression of hsa-miR-27a-3p) and expressed as fold change.
Specifically, the expression data from DASHR and GTEx was normalized to spleen. Likewise, the tissues that were used for correlation analysis of hsa-miR-27a-3p and HMGCR expression were also analyzed for hsa-miR-28 and hsa-miR-708 expression.
Pathway analysis for miR-27a targets.
In order to identify pathways that may be targeted by miR-27a, TargetScan and mirPath v3. tools were employed (Table S2 ). TargetScan relies on an in silico prediction of miRNA targets in a specific pathway while mirPath v3. employs prediction algorithms and experimentally validated miRNA-gene interactions. Interestingly, 21 pathways that were predicted miR-27a targets were commonly enriched in both these tools including steroid biosynthesis, fatty acid metabolism and biosynthesis.
Generation of Hmgcr 3'-UTR/luciferase, mmu-miR-27a promoter/luciferase reporter constructs and miRNA expression plasmids.
To generate the Hmgcr 3'-UTR/luciferase construct, mouse Hmgcr 3'-UTR domain (+20359/+21975 bp) was PCRamplified using Phusion® High Fidelity DNA Polymerase (Finnzymes), mouse genomic DNA (Jackson Laboratory, Bar Harbor, USA) and gene specific primers (FP: 5'-CGTGCTAGCGGATCCTGACACTGAACTG-3', RP: 5'-GCGGCCGGCCTTCAATGTTAACTTCCTTTC -3'). The numberings of the nucleotide positions are with respect to cap site as +1 position. Bold and underlined nucleotides in forward and reverse primers are the restriction sites for NheI and FseI, respectively, that were added to enable cloning of the PCR-amplified 3'-UTR into the firefly-luciferase expressing pGL3-promoter reporter vector (Promega). The purified Hmgcr 3'-UTR PCR product was cloned between XbaI and FseI sites of pGL3-Promoter vector because NheI digested PCR product had compatible ends for XbaI-digested pGL3-promoter reporter vector. Authenticity of the Hmgcr 3'-UTR reporter plasmid was confirmed by DNA sequencing using pGL3-promoter vector sequencing primers [forward primer (1782-1801bp): 5′-CGTCGCCAGTCAAGTAACAA-3′ and reverse primer (2118-2137bp): 5′-CCCCCTGAACCTGAAACATA-3′)];
the resultant plasmid was named as mHmgcr 3'UTR.
To abrogate the binding of miR-27a, 3'UTR-deletion construct was generated using site-directed mutagenesis wherein the putative miR-27a binding site was deleted. The 3'UTR-deletion construct for miR-27a was generated by using the wild-type Hmgcr-3'UTR-reporter construct as template and the following primers: forward, 5'-CGCGGGCATTGGGTTCTCAATTAAAAATCTCAATGCACT-3' and reverse, 5'-AGTGCATTGAGATTTTTAATTGAGAACCCAATGCCCGCG-3'. This deletion in the reporter plasmid was confirmed by DNA sequencing and the resultant construct was named as mHmgcr 27a mut 3'UTR.
The mmu-miR-27a promoter/luciferase reporter construct was generated by amplifying the -1079 bp to +26 bp region of the miR-27a promoter using mouse genomic DNA as described above and primers (forward, 5'-CTAGCTAGCAACTTTAACTGGCACGCAGG-3', and reverse, 5'-CCGCTCGAGGGCATCAAATCCCATCCC-3'). Bold and underlined nucleotides in forward and reverse primers are the restriction sites for NheI and XhoI, respectively, that were added to assist in cloning of the PCR-amplified miR-27a promoter region into the pGL3-basic vector (Promega). The authenticity of resultant construct (referred to as miR-27a promoter) was confirmed by DNA sequencing. In other co-transfection experiments, AML12 cells were transfected with different doses of Egr1 expression plasmid (obtained from Dr. Wong, [11] ) or Egr1 shRNA expression plasmids (obtained from Dr. Xiao, [12] ) along with 500 ng/well of the miR-27a pro construct. In order to maintain equal amount of DNA across transfections, pcDNA3.1/pU6 was used as a balancing plasmid with Egr1/Egr1 shRNA expression plasmid, respectively.
In all co-transfection experiments, cells were lysed 36 hrs post-transfection and cell lysates were assayed for luciferase activity. Luciferase assays were carried out as described previously [13, 14] . Total protein per individual well was also estimated in the same cell lysate using Bradford reagent (Bio-Rad). The reporter activities were normalized with the total protein content and expressed as luciferase activity/µg of protein or % over control.
Animals and tissue samples. containing 0.21%, 20%, 50% and 21% cholesterol, protein, carbohydrate and fat (by weight), respectively (Research Diets) for 10 weeks. All mice received water and food ad libitum. After completion of 10 weeks of diet regimen, the mice were randomly assigned to three groups: HCD-fed mice injected with either saline (n=7) or miRVANA miR-27a mimic (Invitrogen; n=7) or miRVANA negative control oligos (Invitrogen; n=7), respectively.
The miR-27a mimic and negative control oligos were synthesized from Invitrogen, complexed with Invivofectamine 3.0 (Invitrogen) and injected via tail vein at a dose of 5 mg/kg body weight twice over a period of 11 days (second injection after a week of the first dosing). Invivofectamine 3.0 is a lipid nanoparticle delivery system used for the in vivo delivery of miRNAs/siRNAs in rodents. Owing to its safety and efficacy, multiple studies have reported to use of Invivofectamine 3.0 for delivery of miRNA mimic/inhibitors in vivo in mice [16] [17] [18] [19] . For the in vivo delivery of the miR-27a mimic/control oligo, 75 µl of 19.2 µg/µl solution of control oligo/miR-27a mimic was added to equal volume of complexation buffer. This mixture was then diluted with equal volume of Invivofectamine 3.0 and vortexed for a few seconds to ensure miR-27a-Invivofectamine complex formation. The complexes were incubated at 50 °C for 30 min. These complexes were then diluted appropriately with PBS to attain a final concentration of 0.5 mg/ml. Around 200 µl of this formulation was injected into Apoe -/mice via tail-vein. The injected mice were still continued on a high cholesterol diet (HCD) until they were sacrificed. The body weight of the animals was monitored every alternate day. After 4 days of the second dosing, the animals were euthanized by CO2 inhalation followed by cardiac puncture (for blood collection into heparin vials) and the organs were collected in RNAlater (Thermo Fisher) and neutral buffered saline and stored in -80 °C for further analyses. Wistar female rats at the age of 6 weeks were obtained from the King Institute of Preventive Medicine (Chennai, India). Liver, kidneys, heart and skeletal muscle were isolated following standard procedures.
Analysis of biochemical parameters in plasma, blood and tissue samples from the miRNA/ control oligo-treated mice.
Animals were fasted overnight and plasma was collected by spinning the whole blood at 2000 rpm at 4°C for 20 min for measuring total, HDL, LDL cholesterol levels using commercial kits (Randox) as per manufacturer's instructions.
Plasma ALT (alanine aminotransferase), AST (aspartate aminotransferase) and CK (creatine kinase) were also measured using kits (Randox) according to the manufacturer's protocol. For estimating hepatic cholesterol levels, liver tissue (~20 mg) was homogenized in a solvent containing hexane: isopropanol in the ratio 3:2. The lipids were then extracted and tissue total cholesterol was assayed by Amplex Red cholesterol assay kit (Thermo Fisher) as per manufacturer's protocol. For fasting blood glucose measurements, blood was collected via retro-orbital bleed after fasting the animals overnight and the blood glucose levels were measured using an Accu-Chek Active Blood Glucometer (Roche).
RNA extraction and Real-time PCR.
Total RNA was extracted from cell lines and tissue samples by using TRIzol (Invitrogen) as per the manufacturer's instructions. cDNA synthesis was performed using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and miR-27a/miR-27b/U6-specific stem-loop (SL ; Table S3 ) or random hexamer primers. Quantitative real-time PCR (qPCR) was carried out using the DyNAmo HS-SYBR Green qPCR Kit (Finnzymes) and miR-27a/b primers and a universal reverse primer or gene specific primers (Table S3 ). The same mmu-miR-27-forward primer was also used to probe for miR-27b expression.
In certain experiments, AML12 cells were transfected with different doses of miR-27a expression plasmid or 1 µg of miRVANA miR-27a mimic (Invitrogen) and miRVANA negative control oligos (Invitrogen) or 60 nM of locked nucleic acid inhibitor of 27a (LNA 27a) and negative control oligos (Exiqon) using lipofectamine. Overexpression or down-regulation of miR-27a was determined by qPCR analysis.
For cholesterol depletion, AML12 cells (grown in 12 well plates) were treated with increasing doses (0, 1, 3.6 and 5 mM) of cholesterol-depleting reagent methyl-β-cyclodextrin (HiMedia) for 15 min. Cholesterol depletion was carried out in serum-free DMEM medium. Following cholesterol depletion, media was changed with fresh serumfree media and the cells were incubated for 6-9 hrs at 37°C in CO2 incubator. In another series of experiments, AML12 cells were treated with exogenous cholesterol (20 µg/ml) in serum free media for 6-9 hrs. Next, the cells were processed for RNA isolation followed by qPCR to measure the relative abundance of miR-27a and Hmgcr transcript.
Total miRNAs isolated from the treated and control cells were subjected to cDNA synthesis followed by qPCR analysis probing for miR-27a and U6 RNA using miR-27a and U6 specific primers. In all the qPCR analysis, the relative abundance of miR-27a and Hmgcr was determined by calculating 2 -ΔΔCt of each reaction [20] .
Filipin staining of hepatocyte cells.
AML12 cells were seeded at 60-70% confluency in 12/ 24 well plates overnight at 37 °C with 5% CO2. The cells were then treated with 20 µg/ml of exogenous cholesterol or 5mM of cholesterol-depleting reagent methyl-β-cyclodextrin (MCD) for 6 hrs or 15 min, respectively. Post-MCD treatment, the media was changed to serum-free media and the cells were incubated at 37 °C for 6-9 hrs. Following treatment with cholesterol or MCD, the cells were washed with PBS and fixed with 3.6% formaldehyde in PBS for 10 min at room temperature. The fixed cells were washed with PBS and stained with 50 µg/ml of Filipin III (a fluorescent dye that binds to free cholesterol) in the dark at room temperature for 2 hrs. Following fixing, the cells were washed with PBS again and imaged using an Olympus U-RFL-T fluorescence microscope (Olympus).
mRNA stability assays.
Actinomycin D, an extensively used and highly specific transcriptional inhibitor, was used to determine the Hmgcr mRNA stability as described earlier [21] . In this experiment, AML12 cells were transfected with miR-27a plasmid or pcDNA3.1. After 12 hrs of transfection, cells were treated with actinomycin D (5 μg/ml) (Himedia) for different time points (0, 6, 12 and 24 hrs). In both the cases (with/without miR-27a over-expression), Hmgcr mRNA decay was monitored by measuring the Hmgcr levels by qPCR. Hmgcr mRNA half-life was determined by using t1/2= -t (ln2)/ln(Nt/N0) where Nt= mRNA remaining at a specific time t, and N0= mRNA abundance in the beginning. Western blot analysis for Hmgcr level at each time point following Actinomycin D treatment was also performed.
Ago2-Ribonucleoprotein immunoprecipitation (RIP) assays.
Ago2-RIP assays were performed as described previously [22] . HuH-7 cells grown at 60% confluence in 100 mm dishes were transfected with 5 µg of miR-27a plasmid or pcDNA3 using Targetfect F2 transfection reagent (Targeting Systems [23] . All the Western blot experiments were repeated at least three times and representative images are shown.
Chromatin Immunoprecipitation (ChIP) Assays.
AML12 cells, at 60-80% confluency, were cross-linked using formaldehyde at room temperature for 12 min. Next, chromatin was isolated and sheared by sonication followed by a pre- 
RESULTS
Comparative genomics analysis of mouse and rat Hmgcr gene sequences.
Analysis of rat elevated lipid/cholesterol-QTLs on Hmgcr-harboring chromosome 2 within the range of 26000000-28000000 bp detected six lipid-related QTLs (Fig.S1A) ; these QTLs and respective LOD [logarithm (base 10) of odds] scores were retrieved from the Rat Genome Database and are shown in Table S1 . Interestingly, among the QTLs harboring the Hmgcr locus (27480226-27500654 bp, RGD ID: 2803), Stl27 (23837491-149614623 bp) and Stl32
(22612952-67612952 bp) displayed high linkage (LOD score=4.4, 3.2, respectively) with blood triglyceride levels ( Fig.S1A) while Scl55 (26186097-142053534 bp) showed significant linkage with blood cholesterol levels (LOD score=2.83). Moreover, alignment of mouse and rat Hmgcr locus using mVISTA showed >75% homology between these rodents at exons, introns and untranslated regions (Fig.S1B) . Interestingly, the extent of homology between the twenty Hmgcr exons in mouse and rat was higher (>85%) than the noncoding regions ( Fig.S1B) . Thus, mouse Hmgcr appeared as a logical candidate gene for studying the mechanisms of hypercholesterolemia.
Identification of potential miRNAs involved in Hmgcr regulation.
Since miRNA prediction tools employ different algorithms, their outputs may vary and often a set of miRNAs predicted by one tool may not overlap with the others. Hence, in this study we used multiple tools to predict the miRNA binding sites in the 3'-UTR of Hmgcr to increase the accuracy of target predictions. In silico predictions followed by extensive screening procedures shortlisted 7 miRNAs (miR-27a, miR-27b, miR-28, miR-124, miR-345, miR-351 and miR-708; Table S4 ). Since the miR-27a, miR-27b, miR-28 and miR-708 binding sites are highly conserved across mammals including humans, we examined their expression profile in different human tissues using DASHR database. The expression of HMGCR transcript levels in different human tissues was mined from GTEx portal. Interestingly, HMGCR expression showed a significant inverse correlation with the miR-27a expression ( Fig.1D ) (Pearson r = -0.9007, p<0.05). In contrast, miR-27b, miR-28 and miR-708 levels did not exhibit an inverse correlation with HMGCR expression in these tissues (Fig.S2 ). Since the expression of miR-124, miR-345 and miR-351 across various tissues was near/below the detectable range for functional repression of target genes (viz., below 100 RPM) [10] , these were not considered for correlation analysis. Moreover, only miR-27a and miR-27b have been validated to interact with Hmgcr via HITS-CLIP analysis as reported in the TarBase database (Table S2 ). All these lines of evidence indicate a possible role of miR-27a and miR-27b in the post-transcriptional regulation of Hmgcr.
Hence, miR-27a and miR-27b were selected to further investigate their interactions with Hmgcr.
Direct interaction of miR-27a with Hmgcr 3'-UTR down-regulates Hmgcr protein level in hepatocytes.
To examine whether miR-27a directly interacts with Hmgcr, miR-27a expression plasmid was co-transfected with mHmgcr 3'UTR/luciferase construct into AML12 and HuH-7 cells, respectively ( Fig.2A, B) . Indeed, miR-27a overexpression caused a significant dose-dependent reduction in the mHmgcr 3'UTR reporter activity in both AML12 (up to ~85%, p<0.001) and HuH-7 cells (up to ~34%, p<0.01). In contrast, co-transfection of mHmgcr 27a mut 3'UTR construct (devoid of miR-27a binding site) with miR-27a expression plasmid showed no significant change in 3'UTR reporter activity ( Fig.2A, B) . Further, qPCR analysis showed that over-expression of pre-miR-27a led to a dose- RNA fraction immunoprecipitated using pre-immune anti-mouse IgG antibody (control) showed no significant difference in HMGCR levels between miR-27a over-expression and basal conditions (Fig.3E ).
Role of intracellular cholesterol level in miR-27a-mediated regulation of Hmgcr.
Because Hmgcr protein level is dependent on intracellular cholesterol level and regulated by a negative feed-back mechanism, we sought to determine whether modulating endogenous cholesterol level affects the post-transcriptional regulation of Hmgcr. Accordingly, AML12 cells were treated with different concentrations of either cholesterol (5, 10 and 20 µg/ml) or methyl-β-cyclodextrin (MCD, an oligosaccharide that reduces intracellular cholesterol level; 1, 2.5 and 5 mM) followed by Western blot analysis for Hmgcr (Fig.4A, B ). Since 20 µg/ml of cholesterol or 5 mM of MCD showed effective reduction or augmentation in Hmgcr protein level, respectively, these doses were used for further experiments. Interestingly, cholesterol treatment showed ~1.9-fold (p<0.05) enhancement of miR-27a level ( Fig.4C) while cholesterol depletion caused a ~3-fold (p<0.05) reduction in endogenous miR-27a level (Fig.4D ).
Increase/decrease in the intracellular cholesterol level was confirmed by Filipin staining (Fig.4E, F) . Further, Ago2-RIP assays in cholesterol-treated HuH-7 cells revealed significant enrichment of HMGCR (~2.2-fold, p<0.01; Fig.4G ) and miR-27a (~1.7-fold, p<0.001; Fig.4H ) suggesting in vivo interaction of HMGCR with miR-27a under elevated cholesterol conditions.
Role of Egr1 in miR-27a expression under basal and modulated intracellular cholesterol conditions.
To understand the possible mechanism of miR-27a regulation, we predicted transcription factor binding sites in the miR-27a promoter domain (~500 bp) using two programs: LASAGNA and JASPAR (Table S2 ). Egr1, a transcription factor (predominantly expressed in the liver) that plays a crucial role in the transcriptional regulation of most cholesterol biosynthesis genes including Hmgcr [24] , had six putative binding sites as two separate clusters in the miR-27a promoter domain (Fig.5A ).
Next, we validated the role of Egr1 in miR-27a expression by co-transfection experiments. Egr1 overexpression caused a ~3-fold enhancement of miR-27a promoter activity (p<0.0001) ( Fig.5B) while Egr1 downregulation resulted in a ~2.2-fold reduction in miR-27a promoter activity (p<0.05; Fig.5C ). A concomitant increase (~4-fold, p<0.05)/decrease (~2-fold, p<0.05) in the endogenous miR-27a levels upon Egr1 over-expression/downregulation was also observed (Fig.S5 ). Thus, Egr1 may play a crucial role in the transcriptional activation of miR-27a.
Indeed, ChIP (Chromatin Immunoprecipitation) assays confirmed the in vivo interaction of Egr1 with the miR-27a proximal (~-500 bp) promoter domain. qPCR analysis using Egr1 antibody-immunoprecipitated chromatin revealed ~2.5-fold enrichment of the miR-27a promoter domain with P2 primer pair (p<0.001; Fig.5D ) whereas no significant fold-enrichment of the miR-27a promoter domain was observed using primer pair P1 (Fig.5E ) suggesting that the Egr1 sites predicted in this domain (Egr1 cluster 1) may not be functional under basal conditions. Interestingly, Western blot analysis revealed that exogenous cholesterol treatment augmented Egr1 level (Fig.5F ) while its level diminished upon cholesterol depletion (Fig.5G) suggesting that intracellular cholesterol level may regulate miR-27a expression via Egr1. Furthermore, downregulation of Egr1 abrogated the cholesterol-mediated activation of miR-27a promoter activity (Fig.S6) suggesting that Egr1 plays a key role in regulating miR-27a expression under modulated cholesterol levels.
miR-27a mimic reduces hepatic Hmgcr expression and plasma cholesterol levels in high cholesterol diet-fed
Apoe -/mice.
To test if miR-27a mimics can modulate plasma lipid levels in a model of hyperlipidemia, Apoe -/mice on a high cholesterol diet regimen for 10 weeks were injected with either saline or 5 mg/kg dose of miR-27a mimic or control oligo as lipid emulsion formulations (Fig.6A ). Tissue analysis of miR-27a levels revealed ~4-fold (p<0.05), ~5.8-fold (p<0.05) and ~4.3-fold (p<0.05) up-regulation of miR-27a expression in the liver, heart and adipose tissues, respectively, in miR-27a mimic-injected animals as compared to the control oligo group. However, miR-27a levels did not differ in the kidney and brain tissues of miR-27a mimic group as compared to control group (Fig.6B) suggesting efficient delivery of the miR-27a mimic to the liver, heart and adipose tissues.
Western blot analysis in liver tissues of these mice revealed diminished Hmgcr protein level in miR-27a mimic-injected mice as compared to control (Fig.6C, S7A) . The anti-Hmgcr antibody detected a ~120 kDa band suggesting predominantly glycosylated form of the protein in these tissues. The hepatic cholesterol level in miR-27ainjected animals showed a modest decrease, which did not differ significantly in comparison to the control group ( Fig.S7C ).
Next, we assessed the effect of miR-27a mimics on the circulating lipid levels. These parameters were measured 4 days after the second injection of miR-27a mimic/control oligo. Interestingly, the miR-27a mimic group showed reduced plasma total cholesterol (~1.5-fold, p<0.001), LDL cholesterol levels (~1.4-fold, p<0.001) and triglycerides (~1.3-fold, p<0.01) ( Fig.6D, E, F) as compared to the control group. In contrast, miR-27a mimic enhanced the plasma HDL cholesterol levels (~1.5-fold, p<0.05) (Fig.S7B ) in comparison to the control group.
It is important to note that plasma ALT, AST and CK levels were not elevated in this model indicating no obvious liver/muscle injury upon miR-27a mimic injections (Fig.S7D, E, F) . These findings suggest the therapeutic potential of miR-27a mimic as a safe and efficient cholesterol lowering agent.
miR-27a represses Hmgcr by post-translational inhibition followed by mRNA degradation.
In order to unfold the mechanism of action of miR-27a on Hmgcr, mRNA stability assays using actinomycin D were performed in AML12 cells over-expressing miR-27a (Fig.S8) . Interestingly, no significant change in Hmgcr mRNA half-life was observed upon miR-27a over-expression till 24 hours (Fig.S8A, B) . In contrast, the Hmgcr protein levels showed a time-dependent reduction following actinomycin D treatment in AML12 cells transfected with miR-27a ( Fig.S8C, D) . In corroboration, over-expression of miR-27a did not alter steady state Hmgcr mRNA level (Fig.S8E ).
However, 36 hours post-transfection of LNA 27a in AML12 cells, endogenous Hmgcr mRNA levels were significantly enhanced (Fig.S4A) . These observations suggest that Hmgcr repression by miR-27a is mediated predominantly by translational attenuation followed by mRNA degradation.
miR-27a targets multiple genes in the cholesterol regulatory pathways.
In (Figs.9B, C) . In addition, miR-27a augmentation also resulted in diminished expression of lipoprotein uptakerelated genes viz. low density lipoprotein receptor (Ldlr) and Scavenger Receptor Class B Member1 (Scarb1) ( Fig.S4C, D) . Thus, miR-27a seems to play a key role in the global regulation of genes involved in cholesterol homeostasis.
DISCUSSION
Overview
In view of the important role of Hmgcr in cholesterol biosynthesis its potential regulation by microRNAs has been of major interest in recent years. Notably, miR-29a, miR-185, miR-150, miR-548p, miR-21, miR-195 and miR-342 have so far been reported to interact with the Hmgcr transcript [25] [26] [27] [28] [29] [30] [31] . We undertook extensive computational and experimental analyses to identify the key miRNAs that may regulate Hmgcr gene expression under basal as well as pathophysiological conditions. Our in vitro data provides several lines of evidence for regulation of Hmgcr expression by miR-27a (Figs. 1, 2 and 3) . We also observed the effects of miR-27a mimic to down-regulate hepatic expression of Hmgcr and plasma lipid levels in a high cholesterol diet-fed atherosclerotic mouse model (Figs.6, S7 ).
Pathophysiological implications of Hmgcr regulation by miR-27a.
HMGCR is tightly regulated by sterols via transcriptional, post-transcriptional and post-translational mechanisms [32] . In brief, elevated sterols diminish HMGCR expression by inhibiting Sterol Regulatory Element Binding Protein 2 (SREBP-2) transcription factor [33] . The post-transcriptional and post-translational regulatory systems operate independent of SREBP pathway and form an important aspect of sterol-mediated HMGCR regulation. Posttranslational regulation is executed by sterol or non-sterol intermediates via INSIG dependent ER-associated protein degradation (ERAD) mechanism involving ubiquitin-proteasomal degradation of HMGCR [7] . However, the effect of elevated sterols on miRNA-mediated HMGCR regulation is partially understood. In view of crucial role of sterols in HMGCR regulation, do enhanced cholesterol levels modulate endogenous miR-27a levels? Indeed, cholesterol treatment to AML12 cells enhanced miR-27a level and diminished Hmgcr protein level (Fig.4A, C) . In order to rule out the possibility that this repression in Hmgcr protein level is solely because of INSIG-mediated ERAD mechanism, we performed RIP assays in HuH-7 cells treated with cholesterol. Our Ago2-RIP assays further confirmed enhanced interaction of miR-27a with HMGCR under elevated cholesterol level suggesting that post-transcriptional regulation of Hmgcr by miR-27a is an additional mechanism for Hmgcr repression under high cholesterol conditions (Fig.4G,   H ). Thus, this study revealed the crucial role of intracellular cholesterol on Hmgcr expression via miR-27a. This is in corroboration with enhanced miR-27a level in liver tissues of Apoe -/mice fed with a high cholesterol diet regimen as compared to Apoe -/mice fed with a normal chow diet (Fig.S9) .
Are there other microRNAs that modulate lipid or lipoprotein synthesis/secretion into the circulation? There are limited reports on the regulatory roles of miRNAs in cholesterol homeostasis. miR-122 inhibition in mice results in diminished plasma cholesterol and triglyceride levels with reduced fatty acid and cholesterol synthesis [34] .
Interestingly, deletion of miR-122 in mice causes enhanced hepatic lipid, plasma alanine aminotransferase and alkaline phosphatase levels with the development of steatohepatitis, fibrosis and hepatocellular carcinoma (HCC) with age [35] . Likewise, miR-34 over-expression in mice reduced plasma triglyceride and cholesterol levels but augmented hepatic triglyceride levels causing hepatosteatosis [36] . Recent studies indicate that miR-30c lowers plasma cholesterol in different mice models of atherosclerosis, hypercholesterolemia and metabolic disorders without increasing plasma transaminases or causing hepatic steatosis [19, 37] . These studies highlight the potential of miRNAs as therapeutic agents in the treatment of hypercholesterolemia.
For validation of our in vitro findings, we tested the effect of miR-27a mimic in high cholesterol diet-fed
Apoe -/mice. An improved lipid-based formulation was employed for the efficient delivery of the miR-27a mimic via tail vein injection to major organs viz. the liver, heart and adipose tissues as confirmed by the tissue analysis of miR-27a levels (Fig.6B ). Administration of miR-27a over a period of 11 days induced a significant reduction in the plasma total cholesterol, LDL cholesterol and triglyceride levels with a concomitant increase in the HDL cholesterol levels ( Fig.6D, E, F, Fig.S7B ).
miR-27a appears to diminish the plasma cholesterol levels by reducing the Hmgcr protein level in the liver (Fig.6C, S7A ). The reductions in the plasma triglycerides are consistent with a previous report wherein miR-27a expression diminished triglyceride levels in mouse hepatocytes mainly by targeting fatty acid synthase (Fas) and
stearyl CoA desaturase 1 (Scd1) [38] . We speculate that the increase in plasma HDL cholesterol level might result from the miR-27a-mediated regulation of Scarb1, an HDL cholesterol receptor (Fig.S4D ). It is interesting to note that the food-derived remnant cholesterol has a modest contribution to the total cholesterol level. Moreover, it has been previously reported that remnant lipoproteinemia in APOE -/minipigs is not efficient in initiating atherosclerosis but contributes to the atherosclerotic progression of pre-existing lesions [39] . Therefore, miR-27a mimic may diminish the overall plasma total cholesterol levels in high cholesterol diet-fed Apoe -/mice by modulating the LDL, HDL and other cholesterol fractions.
Does the miR-27a mimic treatment cause any adverse effects in the diet-induced atherosclerosis mouse model? We did not detect any significant changes in plasma ALT, AST and CK levels suggesting that the animals did not suffer from any liver or muscle injury (Fig.S7D, E, F) . However, additional studies are required to test the longterm effects of the miR-27a mimic to further evaluate its therapeutic potential
Molecular mechanisms of Hmgcr regulation by miR-27a.
Generally, miRNAs exert their action by translational inhibition followed by mRNA deadenylation, decapping and decay [40] . Our actinomycin D chase experiments showed that Hmgcr mRNA half-life did not change whereas the Hmgcr protein level diminished in a time-dependent manner (Fig.S8) . Consistently, the steady-state Hmgcr mRNA level in hepatocytes did not diminish upon miR-27a over-expression ( Fig.S8 ). However, Hmgcr mRNA levels were significantly altered at time points exceeding 24 hours of transfection in hepatocytes or miR-27a mimic injection in Apoe -/mice (Fig.S4A, Fig.7C ). These observations are consistent with a previous report which suggests that miRNAs initially reduce target protein levels without affecting mRNA levels but diminish mRNA levels at later time points [41] . Therefore, we speculate that miR-27a-mediated Hmgcr repression mainly involves translational control followed by mRNA degradation.
In view of the key role of miR-27a in regulating Hmgcr, we sought to unravel how miR-27a might be regulated under basal and pathophysiological conditions. Computational and experimental analyses suggested a crucial role of Egr1 in the activation of miR-27a expression. Egr1, a zinc finger transcription factor belonging to the early growth response gene family, binds to a GC-rich consensus region [42] and regulates genes involved in physiological stress response, cell metabolism, proliferation and inflammation [43] . Egr1, majorly expressed in the liver, targets multiple cholesterol biosynthesis genes [24, 44] . In light of putative Egr1 binding sites in the proximal miR-27a promoter domain (Fig.5A) , we investigated the role of Egr1 in miR-27a expression. Indeed, overexpression/down-regulation of Egr1 resulted in enhanced/diminished miR-27a promoter activity in AML12 cells ( Fig.5B, C) . ChIP assays also confirmed the in vivo interaction of Egr1 with the miR-27a promoter (Fig.5D ).
Therefore, our results suggest that Egr1 regulates miR-27a expression under basal conditions.
Role of miR-27a in global regulation of cholesterol homeostasis.
miR-27a, an intergenic miRNA, is transcribed from the miR-23a-miR-27a-miR-24 cluster located on chromosome 8 in mice. Dysregulation of miR-27a has been associated with several cardiovascular phenotypes including impaired left ventricular contractility, hypertrophic cardiomyopathy, adipose hypertrophy and hyperplasia [45] . miR-27a has been reported to regulate several genes involved in adipogenesis and lipid metabolism including Retinoid X receptor alpha (RXRα), ATP-binding cassette transporter (ABCA1) also known as the cholesterol efflux regulatory protein, fatty acid synthase (FASN), sterol regulatory element-binding proteins (SREBP-1 and -2), peroxisome proliferator-activated receptor (PPAR-α and -γ), Apolipoprotein A-1, Apolipoprotein B-100 and Apolipoprotein E-3 [46] . In addition, miR-27a has been reported to play a role in the regulation of Ldlr [47] . Our in vitro and in vivo experiments revealed that miR-27a targets Mvk, Fdft1, Sqle, Ggps1 and Mvd in the cholesterol biosynthesis pathway (Fig.7) .
Consistent with our findings, administration of miR-27a mimic in Apoe -/mice diminished lipid levels in both plasma and peritoneal macrophages, thereby alleviating atherosclerosis by targeting macrophage-derived lipoprotein lipase (Lpl) [48] . Of note, HITS-CLIP experiments revealed that miR-27a also targeted microsomal triglyceride transfer protein (Mttp), a crucial chaperone involved in lipoprotein production [49] . Further, global pathway analysis for miR-27a targets revealed 21 pathways including steroid biosynthesis, fatty acid metabolism and biosynthesis (Fig.S10) .
Thus, miR-27a contributes to global regulation of cholesterol homeostasis by targeting multiple genes in lipid synthesis, lipoprotein synthesis and uptake.
Limitations of the study.
Although our findings indicate that miR-27a mimic lowers plasma cholesterol levels considerably, there are some challenges that remain unaddressed. First, a less-/non-invasive method of delivery (viz. subcutaneous or oral route) over intravenous injections would be desirable for easy administration of the mimic. Second, improved lipid formulations or nanoparticle-mediated delivery would considerably reduce the amount of mimic required and eliminate the need for frequent injections. Additionally, further chemical modifications to this mimic may attribute to increased target specificity and confer resistance to nuclease activity. Moreover, extensive assessment of biological and pharmacological effects of miR-27a mimic in animal models are necessary to evaluate its long-term safety and efficacy as a therapeutic agent.
Conclusions and perspectives.
This study identified miR-27a as a crucial regulator of cholesterol biosynthesis pathway. Egr1 modulates miR-27a expression under basal and elevated cholesterol conditions. miR-27a directly interacts with the 3'-UTR of Hmgcr and miRNA therapeutics is an emerging and promising avenue to treat a wide array of human diseases. A fine balance between lipid/lipoprotein synthesis and lipoprotein uptake is essential for cholesterol homeostasis and dysregulation of one or more pathways could lead to drastic effects. Therefore, miRNAs targeting multiple related pathways may be more efficacious in lowering plasma lipids than the conventional approach of targeting individual proteins/pathways. In view of the ability of miR-27a to target several crucial genes in the cholesterol biosynthesis pathway, miR-27a mimic may emerge as a promising therapeutic intervention to lower plasma cholesterol. Thus, our findings and other studies provide strong impetus for further evaluation of miR-27a as a novel lipid-lowering agent. 
